3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
56
Breast Neoplasms
50
Ovarian Neoplasms
33
Triple Negative Breast Neoplasms
27
Endometrial Neoplasms
25
Lung Neoplasms
24
Neoplasm Metastasis
23
Fallopian Tube Neoplasms
23
Squamous Cell Carcinoma of Head and Neck
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Neoplasms
14
Esophageal Squamous Cell Carcinoma
12
Esophageal Neoplasms
12
Carcinoma, Ovarian Epithelial
9
Stomach Neoplasms
8
Head and Neck Neoplasms
8
Colorectal Neoplasms
8
Carcinoma
8
Adenocarcinoma Of Esophagus
7
Adenocarcinoma
7
Peritoneal Neoplasms
6
Uterine Cervical Neoplasms
5
Melanoma
5
Small Cell Lung Carcinoma
4
Oropharyngeal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Transitional Cell
4
Uterine Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Non-small Cell Lung Cancer
×
Paclitaxel
×
90 days
×
Clear all
NCT07221474
2026-06-09
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled